Sami Karaborni
30Patents
2h-index
33Co-inventors
53Inventor score
Filing activity: Oct 19, 2009 → Jan 24, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11395801B2 | Modified release compositions of a gamma-hydroxybutyric acid derivative | Human Necessities | 6 | Active |
| US10865198B2 | Solid forms of cerdulatinib | Chemistry; Metallurgy | 3 | Active |
| US10179118B2 | Pharmaceutical compositions of dimethyl fumarate | Human Necessities | 2 | Active |
| US10576055B2 | Pharmaceutical compositions of dimethyl fumarate | Human Necessities | 1 | Active |
| US11229621B2 | Pharmaceutical compositions of dimethyl fumarate | Human Necessities | 1 | Active |
| US9416096B2 | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use | Emerging Cross-Sectional Technologies | 1 | Active |
| US9421182B2 | Cocrystals of dimethyl fumarate | Emerging Cross-Sectional Technologies | 1 | Active |
| US8399513B2 | Levodopa prodrug mesylate hydrate | Chemistry; Metallurgy | 1 | Active |
| US12337066B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | Human Necessities | 0 | Active |
| US10716760B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11661414B2 | Solid forms of Cerdulatinib | General | 0 | Revoked |
| US9895336B2 | Crystalline forms of (N, N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use | Emerging Cross-Sectional Technologies | 0 | Active |
| US11925710B2 | Modified release compositions of a GAMMA-hydroxybutyric acid derivative | Human Necessities | 0 | Active |
| US11304906B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | Human Necessities | 0 | Active |
| US11357734B2 | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients | Human Necessities | 0 | Active |
| US12396966B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | Human Necessities | 0 | Active |
| US11135296B2 | Pharmaceutical compositions of fumaric acid esters | Human Necessities | 0 | Active |
| US12006318B2 | Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US11938111B2 | Pharmaceutical compositions of dimethyl fumarate | Human Necessities | 0 | Active |
| US8722733B2 | Levodopa prodrug mesylate hydrate | Chemistry; Metallurgy | 0 | Active |
| US11690811B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | Human Necessities | 0 | Active |
| US10945984B2 | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects | Human Necessities | 0 | Active |
| US9999672B2 | Pharmaceutical compositions of fumaric acid esters | Human Necessities | 0 | Active |
| US11713309B2 | Solid forms of Cerdulatinib | Chemistry; Metallurgy | 0 | Active |
| US10940117B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.